American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

American Century Companies Inc. grew its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,448 shares of the company’s stock after acquiring an additional 12,162 shares during the period. American Century Companies Inc. owned about 0.10% of Tango Therapeutics worth $341,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TNGX. State Street Corp raised its holdings in shares of Tango Therapeutics by 26.8% during the third quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares in the last quarter. Geode Capital Management LLC raised its holdings in Tango Therapeutics by 11.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after purchasing an additional 142,710 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Tango Therapeutics by 18.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,237 shares of the company’s stock valued at $3,752,000 after purchasing an additional 76,540 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Tango Therapeutics during the fourth quarter valued at about $218,000. Finally, Barclays PLC raised its stake in Tango Therapeutics by 78.3% in the third quarter. Barclays PLC now owns 126,281 shares of the company’s stock worth $972,000 after buying an additional 55,470 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 24,268 shares of company stock valued at $72,561 in the last three months. Company insiders own 6.30% of the company’s stock.

Tango Therapeutics Stock Performance

Tango Therapeutics stock opened at $1.41 on Monday. Tango Therapeutics, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $12.02. The stock has a market cap of $152.43 million, a price-to-earnings ratio of -1.19 and a beta of 1.03. The stock’s 50 day simple moving average is $1.96 and its two-hundred day simple moving average is $3.45.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $7.84 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. On average, analysts predict that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.